<DOC>
	<DOCNO>NCT02656524</DOCNO>
	<brief_summary>The study aim evaluate use regorafenib clinical practice Hungary . The study provide information clinical characteristic Hungarian regorafenib patient well information safety efficacy regorafenib Hungarian patient metastatic colorectal cancer . This much need data require National Health Insurance Fund order accept regorafenib regular reimbursement system . This study propose base patient data Hungarian National Health Insurance Fund 's Database . Data analyze include patient demography baseline tumor characteristic , overall survival , time treatment failure , duration treatment , average dose dose modification , adverse event . Further , treatment cost estimate .</brief_summary>
	<brief_title>Stivarga Real Life Evidence Hungary</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Using National Health Insurance Database , patient include retrospective data analysis least one dose regorafenib treatment cycle ( =28 day ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Metastatic colorectal cancer</keyword>
</DOC>